President Trump Enacts 100% Tariffs on Patented Pharmaceuticals, Reshaping U.S. Drug Market
On April 2, 2026, President Trump signed an executive order imposing a 100% tariff on patented pharmaceutical products and their active ingredients, effective July 31, 2026, for large companies and September 29, 2026, for smaller manufacturers. This order, under Section 232 of the Trade Expansion Act of 1962, aims to bolster national security and strengthen U.S. supply chains. Generic drugs, biosimilars, and certain specialty products are currently exempt, with a review of generics planned within a year. The tariffs are part of a broader strategy to encourage domestic pharmaceutical production and reduce reliance on foreign imports.